La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Fitell a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Fitell..

Fitell (NASDAQ:FTEL) Azioni, Catena delle Opzioni

Fitell

Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.

Fitell Corp

U.S. stock futures dipped into the red after a brief rise Monday morning, as tensions continue to flare in the Middle East, following <a href="https://www.benzinga.com/news/politics/25/06/46042703/iran-calls-us-bombing-of-nuclear-sites-very-very-dangerous-for-everybody">American airstrikes</a> on Iranian nuclear facilities over the weekend.
Investors are on the edge, with potential for further escalation in the crisis, following Iran&#8217;s parliament voting on Sunday to <a href="https://www.benzinga.com/news/politics/25/06/46044009/us-iran-tensions-escalate-as-iran-threatens-hormuz-closure-potentially-rattling-global-oil-markets">authorize the closure</a> of the Strait of Hormuz. 
The 10-year Treasury bond yielded 4.397%, and the two-year bond was at 3.927%. The CME Group&#8217;s FedWatch&nbsp;<a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html" target="_blank" rel="noreferrer noopener">tool</a>‘s projections show markets pricing an 85.5% likelihood of the Federal Reserve keeping the current interest rates unchanged in its next FOMC meeting in late July.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.24%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.19%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.22%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.55%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, and the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the Nasdaq 100 index, were both trading lower in pre-market by 0.13% and 0.23%, respectively, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;idm7up&#x2A;_gcl_au&#x2A;OTU0MzA1MzE4LjE3NDcwMTIxNDM.&#x2A;_ga&#x2A;ZGVsZXRlZA..&#x2A;_ga_V7ZK73W7N0&#x2A;czE3NTA2NjM1NzckbzIzNCRnMSR0MTc1MDY2NzQzNCRqNjAkbDAkaDA.">Benzinga Pro</a> data.
Cues From Last Session:
The S&amp;P 500 ended down 0.22% on Friday, with a mixed sector-wise performance. Tech, healthcare, materials, and communications led the decline, while energy, consumer staples, and utilities rose higher, with energy leading the way, up 1.02% during the day.
The Dow Jones Industrial Average was flat during the day, up just 0.08% or 35 points, ending the week at 42,206.82 points, following a volatile session.
Drywall and insulation contractor, GMS Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>), rallied 23.77% during the day, after becoming an acquisition target of building products company, QXO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>), which was followed by a string of hikes in the stock&#8217;s price targets, with the high end now at $105, representing a 5% upside from current levels.
The Philadelphia Fed manufacturing survey posted a 4% decline, compared to an analyst consensus of a 2% decline, while the U.S. Leading Economic Indicators release reported a 0.1% decline, in line with forecasts.
The Dow Jones index ended 35.16 points or 0.083% up at 42,206.82, whereas the S&amp;P 500 index fell 0.22% to 5,967.84. Nasdaq Composite declined 0.51% to 19,447.41, and the small-cap gauge, Russell 2000, tumbled 0.17% to end the week at 2,109.27.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.51%</td>
<td>19,447.41</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.22%</td>
<td>5,967.84</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.08%</td>
<td>42,206.82</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.51%</td>
<td>19,447.41</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
As tensions continued to flare between Israel, the U.S., and Iran, leading analysts remain optimistic regarding the market at the start of the new week.
Leading tech analyst, Dan Ives, shared on Sunday, in a post on X, that <a href="https://www.benzinga.com/news/politics/25/06/46045276/dan-ives-says-iran-threat-is-in-rear-view-mirror-calls-it-positive-for-the-middle-east-and-the-tech-sector">the Iran threat</a> was now in the &#8220;rear-view&#8221; for the markets. He added that the events that took place over the weekend will be seen as &#8220;a positive&#8221; for growth and stability in the Middle East. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The market will view this Iran threat as now gone and that is a positive for growth in the broader Middle East and ultimately the tech sector. It will take some time for this conflict to settle, but the market will view the worst is now in the rear-view mirror. Expect stocks up
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1936772081804292391?ref_src=twsrc%5Etfw">June 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Iran has vowed to respond to the strikes, declaring it "reserves all options" in the face of U.S. aggression.
Chartered Market Technician, Ryan Detrick, however, cautioned of a pullback in the markets, often seen in late-June or early-July in a post-election year.
&#8220;The headlines are the headlines, but don&#8217;t forget that late June/early July tends to be weak in a post-election year,&#8221; he said on X.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The headlines are the headlines, but don&#39;t forget that late June/early July tends to be weak in a post-election year. <a href="https://t.co/pnRULgmhRY">pic.twitter.com/pnRULgmhRY</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1936932156653056070?ref_src=twsrc%5Etfw">June 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Upcoming Economic Data:
Here&#8217;s what investors will be focused on, when markets open on Monday,
<ul class="wp-block-list">
<li>S&amp;P Flash U.S. Services PMI, along with the S&amp;P Flash U.S. Manufacturing PMI, is set to be released at 9:45 AM ET on Monday. </li>
<li>The Existing Home Sales data is set to be unveiled by 10:00 AM.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>FactSet Research Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>), a financial data provider, is set to release its third quarter results by 9 AM on Monday morning, before markets open. The stock is up 0.04% pre-market. </li>
<li>Commercial Metas Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) will be announcing its third quarter results by 11:00 AM, and the stock is up 6.20% pre-market. </li>
<li>KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>), a homebuilding company, is scheduled to announce its second quarter figures after markets close on Monday. The stock is down 0.44% pre-market. </li>
<li>PACS Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>), an operator of skilled-nursing care facilities, is expected to announce its quarterly results after markets close.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures are up 0.49% in the early New York session, with prices hovering around $74.19 per barrel, well below the day&#8217;s high of $77.13.
Gold Spot US Dollar was down 0.06%, trading at $3,366.61 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index (DXY) spot was up 0.35% at the 99.268 level.
Asian markets were mixed on Monday, with China&#8217;s Shanghai and Shenzhen indices up, while Japan&#8217;s Nikkei 225, the KOSPI, and India&#8217;s Nifty 50 ended the day lower.
Photo: Shutterstock

News

Pre-Market Outlook

PACS

US Stocks Likely To Open Lower As Iran Vows Retaliation After US Strike: 'Worst Is Now In The Rear-View Mirror,' Says Top Analyst (UPDATED)

JP Morgan analyst Daniel Politzer initiates coverage on Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Overweight rating and announces Price Target of $47.

Price Target

Initiation

Analyst Ratings

JP Morgan Initiates Coverage On Caesars Entertainment with Overweight Rating, Announces Price Target of $47

BMO Capital analyst John Kim maintains BXP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) with a Outperform and raises the price target from $85 to $86.

BMO Capital Maintains Outperform on BXP, Raises Price Target to $86

Key Transaction Terms
Under the terms of the Merger Agreement, a merger subsidiary incorporated in Nevada as a PubCo subsidiary will merge with and into Impact BioMedical, with Impact BioMedical being the surviving entity. Simultaneous with or immediately following the merger, PubCo shall acquire all of the issued and outstanding shares of Dr Ashleys Bio Labs Limited, a Cayman Islands exempted company holding all shares of Dr. Ashleys. As a result of the Transaction, Impact BioMedical and Dr. Ashleys shall become wholly-owned subsidiaries of PubCo. Upon closing, the PubCo will be operated by the management team of Dr Ashleys, with a new Board of Directors to be assembled by Dr Ashleys.
The Boards of Directors of both Dr Ashleys and Impact BioMedical have unanimously approved the proposed Transaction, subject to, among other things, approval by Impact BioMedical's shareholders, and satisfaction (or waiver, as applicable) of the conditions provided in the Merger Agreement, including regulatory approvals and other customary closing conditions, including an effective registration statement on Form F-4 or S-4 in connection with the proposed Transaction being declared effective by the U.S. Securities and Exchange Commission (the "SEC") and the approval of listing applications with the New York Stock Exchange.
Additional information about the proposed Transaction, including a copy of the Merger Agreement, will be provided in a Current Report on Form 8-K to be filed by Impact BioMedical with the SEC and available at <a href="http://www.sec.gov/">www.sec.gov</a>. Additional information about the proposed Transaction will be described in the registration statement on Form F-4 or S-4, which will be filed by the newly formed PubCo with the SEC.

Impact BioMedical And Dr Ashleys Limited Announce Merger And Share Exchange Agreement; Dr. Ashleys To Acquire Impact BioMedical Through A Reverse Merger

JP Morgan analyst Daniel Politzer initiates coverage on Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) with a Overweight rating and announces Price Target of $116.

CHDN

JP Morgan Initiates Coverage On Churchill Downs with Overweight Rating, Announces Price Target of $116

Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the addition of Tel Aviv Sourasky Medical Center (TASMC), Tel Aviv, Israel, as an additional clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This expansion follows the recent enrollment of the first patient in the trial, announced on June 5, 2025, marking a significant milestone in the development of CMND-100.
The study at Tel Aviv Sourasky Medical Centerwill be led by Dr. David Zeltser, Director of the Emergency Medicine Department. Tel Aviv Sourasky Medical Center joins other prestigious institutions participating in the trial, including Yale School of Medicine's Department of Psychiatry, Johns Hopkins University School of Medicine in the United States. The inclusion of Tel Aviv Sourasky Medical Center further strengthens Clearmind's clinical network, enhancing the trial's capacity to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring its potential to reduce alcohol cravings and consumption in patients with AUD.

CMND

Clearmind Adds Tel Aviv Hospital to Psychedelic Drug Trial for Alcohol Use Disorder

CARM

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

SPTN

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

Dr Ashleys Limited, a Hong Kong based global pharmaceutical company ("Dr Ashleys"), and Impact BioMedical Inc. ("Impact BioMedical") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American ("Impact BioMedical", together with Dr Ashleys, the "Parties"), are pleased to announce the execution of a merger and share exchange agreement (the "Merger Agreement") on June 21, 2025 to enter into a strategic merger transaction (the "Transaction"). Upon closing of the Transaction, Dr. Ashleys will acquire Impact BioMedical through a reverse merger that will result in a newly formed combined entity (the "PubCo") traded on the NYSE American under the name "Dr Ashleys Limited."
The Transaction marks a strategic move that underscores the growing importance of innovation and collaboration in the biomedical industry. With Dr Ashleys' global reach and financial capabilities, the potential for Impact BioMedical's patents to reach the market has never been greater.
Statements from Leadership
Dr. Kanans Visvanats, Director of Dr. Ashleys Limited, stated: "This merger represents a significant milestone in our journey to bring innovative pharmaceutical treatments to patients worldwide. By integrating Impact Biomedical's impressive&nbsp;IP portfolio into our R&amp;D efforts, we are poised to accelerate the development of groundbreaking therapies and expand our Impact on global health."
Frank D. Heuszel, CEO of Impact Biomedical Inc., commented: "We are thrilled to join forces with Dr. Ashleys Limited. Their global reach and financial strength will provide the resources and infrastructure needed to bring our innovations to market, ultimately benefiting people around the world."
Key Transaction Terms
Under the terms of the Merger Agreement, a merger subsidiary incorporated in Nevada as a PubCo subsidiary will merge with and into Impact BioMedical, with Impact BioMedical being the surviving entity. Simultaneous with or immediately following the merger, PubCo shall acquire all of the issued and outstanding shares of Dr Ashleys Bio Labs Limited, a Cayman Islands exempted company holding all shares of Dr. Ashleys. As a result of the Transaction, Impact BioMedical and Dr. Ashleys shall become wholly-owned subsidiaries of PubCo. Upon closing, the PubCo will be operated by the management team of Dr Ashleys, with a new Board of Directors to be assembled by Dr Ashleys.
The Boards of Directors of both Dr Ashleys and Impact BioMedical have unanimously approved the proposed Transaction, subject to, among other things, approval by Impact BioMedical's shareholders, and satisfaction (or waiver, as applicable) of the conditions provided in the Merger Agreement, including regulatory approvals and other customary closing conditions, including an effective registration statement on Form F-4 or S-4 in connection with the proposed Transaction being declared effective by the U.S. Securities and Exchange Commission (the "SEC") and the approval of listing applications with the New York Stock Exchange.

IPOs

Dr Ashleys to Go Public via Merger With Impact BioMedical in NYSE Deal

JP Morgan analyst Daniel Politzer initiates coverage on Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) with a Neutral rating and announces Price Target of $79.

JP Morgan Initiates Coverage On Boyd Gaming with Neutral Rating, Announces Price Target of $79

Crescent Energy Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) ("we" or "our") announced today that, subject to market conditions, its indirect subsidiary Crescent Energy Finance LLC (the "Issuer") intends to offer for sale in a private placement pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the "Securities Act"), to eligible purchasers, $500 million aggregate principal amount of Senior Notes due 2034 (the "Notes"). The Notes will be guaranteed on a senior unsecured basis by all of the Issuer's subsidiaries that guarantee the Issuer's existing notes and the indebtedness under its revolving credit facility (the "revolving credit facility").
The Issuer intends to use the net proceeds from this offering, together with additional borrowings under the revolving credit facility and cash on hand, if needed, to fund the tender offer to purchase for cash up to $500 million aggregate principal amount of the Issuer's outstanding 9.250% Senior Notes due 2028 (the "2028 Notes"), pursuant to the tender offer that commenced concurrently with this offering (the "Tender Offer"), and any fees and expenses in connection therewith or with this offering. Any portion of the net proceeds from this offering that is not used to fund the consummation of the Tender Offer will instead be used to repay amounts outstanding under the revolving credit facility or for general corporate purposes. This offering is not contingent on the consummation of the Tender Offer. The Tender Offer is subject to the satisfaction of certain conditions, including, but not limited to, the completion of this offering.

Offerings

CRGY

Crescent Energy Plans $500M Bond Sale to Help Refinance High-Interest 2028 Notes

With social media oversharing, ubiquitous data brokers, and polarizing public discourse being the new norm, the online privacy of high-ranking executives isn't just a personal matter anymore. It's a corporate concern. CEOs, CFOs, and other public-facing business leaders are increasingly in the crosshairs of executive doxxing, the act of publishing personally identifiable information online with malicious intent.
While doxxing was once largely associated with internet activism or personal vendettas, it's now overlapping with the business world in disconcerting ways. From politically motivated campaigns to financially driven harassment, executives are being exposed and exploited through their digital footprints. And let's face it: companies are bearing the brunt of it.
<h2 class="wp-block-heading">When Executive Privacy Becomes a Corporate Risk</h2>
The reputational damage and security risks associated with doxxing can be staggering. In some cases, an executive's leaked address or family member's name has led to real-world threats, social engineering attempts, or disruptive protests. Even when these incidents don't escalate into physical danger, they can consume resources, <a href="https://www.benzinga.com/news/24/06/39175485/michael-cohens-family-doxxed-after-trumps-hush-money-conviction-says-ex-trump-attorney-what-sad-time">spark media blowback</a>, and erode stakeholder trust.
For publicly traded companies, such episodes can potentially have financial repercussions. Investor confidence wavers when leadership appears vulnerable. This is especially true for industries where the perception of security and discretion is paramount, such as finance, tech, and defense.
Moreover, a growing number of targeted cyberattacks begin with publicly available data scraped from people-search sites, social platforms, or public records. This makes the digital footprint of corporate leaders a natural entry point for malicious actors.
<h2 class="wp-block-heading">Why Traditional Security Strategies Fall Short</h2>
Most corporations invest heavily in cybersecurity infrastructure, physical access controls, and high-level legal protections for the people upstairs. These strategies tend to focus on the perimeter, shielding company data, devices, and networks. While worthwhile, such mechanisms often turn a blind eye to the ecosystem of personal data scattered across the internet. And that's precisely where doxxers look first.
Here's some food for thought: numerous data broker sites legally aggregate and sell personal information such as home addresses, previous residences, email addresses, and more. This information is typically compiled without consent and made publicly searchable, offering a dossier for anyone with a grudge or a motive.
Alarmingly, senior executives can be clueless about how exposed their personal details are, and few have the time or know-how to address this on their own.
<h2 class="wp-block-heading">Proactive Privacy as a New Breed of Executive Defense</h2>
To tackle this threat, more organizations are beginning to intertwine personal data removal strategies into their broader executive protection plans. These strategies aim to eliminate or suppress personal details from data broker sites, people-search platforms, and other online repositories. The options range from niche consulting firms to privacy services that specialize in large-scale data removal.
For instance, platforms that automate the process of requesting <a href="https://blog.incogni.com/opt-out-guides/">opt out</a> from dozens (sometimes hundreds) of data brokers can save executives the time and hassle of interacting with each site individually. This approach can be integrated into onboarding or risk mitigation programs for C-level roles and public-facing personnel.
The counterintuitive part is that data removal isn't necessarily reactive. It can be preventive. Regular monitoring and removal reduce the surface area that attackers or agitators can exploit. This makes executive doxxing attempts harder and less effective from the get-go.
<h2 class="wp-block-heading">Building a Culture of Privacy Awareness at the Top</h2>
Organizations looking to protect their leadership must foster a culture of privacy mindfulness, and the process starts from the top. Executives often serve as both brand ambassadors and decision-makers. That means their personal behavior online can have cascading effects on the company.
That being said, key steps to institutionalize enterprise-wide privacy resilience include:
<ul class="wp-block-list">
<li>Training and awareness: C-suite members should understand the mechanics of executive doxxing and the ways their digital presence fuels personal and corporate risk.</li>
<li>Audit and visibility: Conduct regular assessments of what personal data is publicly available on executives and directors.</li>
<li>Policy integration: Incorporate privacy protocols into contracts and executive onboarding procedures.</li>
<li>Digital compartmentalization: Encourage leaders to keep personal accounts, devices, and apps separate from business-facing ones, and to <a href="https://support.microsoft.com/en-us/topic/the-dangers-of-oversharing-79330a32-4ee1-433a-812e-fe4bb3d34511">avoid oversharing online</a>.</li>
</ul>
It's not about asking leaders to become digital recluses. Instead, it's about understanding that the countermeasures for personal data exposure are just as important as protecting internal systems.
<h2 class="wp-block-heading">From Afterthought to Business Commitment</h2>
The line between personal privacy and organizational security continues to blur. This is increasingly evident in the area of executive doxxing. As visibility increases for public-facing professionals, so does the need to anticipate and deflect potential attacks on their personal lives.
For companies, this means that protecting executives goes beyond installing cameras or monitoring access logs. It's about limiting how much of their data can be pulled up with a few clicks and a search engine. The less exposed the individual, the safer the organization.
Incorporating privacy tools and data removal services into your company's executive protection playbook is a strategic foresight rather than an overkill. It <a href="https://www.benzinga.com/news/events/24/08/40554802/from-data-centers-to-the-cloud-transition-creates-new-challenges-for-it-pros-analyst-says">acknowledges</a> that the most sensitive information isn't necessarily stored on a company server these days. Sometimes, it's a home address listed on page three of a people-search website, waiting for the wrong person to find it.

Opinion

General

When C-Suite Privacy Becomes A Corporate Risk: How To Combat Executive Doxxing

JP Morgan analyst Daniel Politzer initiates coverage on Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) with a Overweight rating and announces Price Target of $101.

JP Morgan Initiates Coverage On Wyndham Hotels & Resorts with Overweight Rating, Announces Price Target of $101

JP Morgan analyst Daniel Politzer initiates coverage on Sunstone Hotel Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHO#NYSE">SHO</a>) with a Underweight rating and announces Price Target of $8.

JP Morgan Initiates Coverage On Sunstone Hotel Invts with Underweight Rating, Announces Price Target of $8

BMO Capital analyst John McNulty downgrades Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from Market Perform to Underperform and lowers the price target from $29 to $22.

Downgrades

BMO Capital Downgrades Dow to Underperform, Lowers Price Target to $22

Siyata Mobile Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>, SYTAW)) ("Siyata" or the "Company"), a global developer and vendor of mission-critical Push-to-Talk over Cellular (PoC) handsets and accessories, today announced that Core Gaming, a rising innovator in AI-driven creative technologies, who it recently signed a definitive merger agreement with, is experiencing continued momentum with its innovative AI COMIC app.
&nbsp;
In less than one year, combined user numbers of AI COMIC in Japan and South Korea have jumped from 2,500 to over 32,000, a 13x increase, while those countries' share of total global users rose from 4.12% to 14.38%.
"AI COMIC's breakout success in Japan and South Korea is a powerful validation of our strategic vision," said Aitan Zacharin, CEO of Core Gaming. "Return on investment in the region has more than tripled, driven by targeted localization efforts such as a language-optimized user interface. Just as important, the virality we are seeing through widely used platforms like TikTok and Facebook underscores how deeply users are engaging with our product."
Launched to broad interest, AI COMIC blends next-gen AI capabilities with a uniquely immersive user experience. The app empowers users to transform everyday visuals into vivid anime-style content through features such as AI-generated video, personalized avatars, manga scene recreation, time-lapse aging and realistic face swaps.
Zacharin continued, "AI COMIC runs on a robust technological foundation built on our proprietary Compute Pool System, multimodal generative AI models and a scalable cloud orchestration architecture that is redefining content creation and distribution. Importantly, our goal is not just to build apps. We are building a robust, scalable AI infrastructure designed to power creative expression on a global scale. AI COMIC is only the beginning."
Technology Platform: A Breakthrough AI Engine
While AI COMIC continues to attract headlines and users, the underlying technology is the true differentiator. To support rapid growth and creative demand, Core Gaming built a smart, cloud- based infrastructure that delivers scalable AI performance while keeping costs efficient. This foundation enables the platform to streamline game asset creation—from automated scene and character generation to fast, high-quality animations and ad creatives—helping content teams iterate faster and bring ideas to life with minimal effort.
Core Gaming's AI infrastructure is designed around three core pillars:
<ul>
<li>Compute Pool System (CPS) is a dynamic AI task distribution engine that allocates computational resources across workloads in real time. CPS ensures optimal throughput for video generation, avatar rendering and real-time user interactions—without overprovisioning infrastructure. &nbsp;</li>
<li>Multimodal Generative Models that process and synthesize visual, text and audio inputs simultaneously, enabling complex creative outputs such as dialogue-driven animation, mood-based styling, and high-resolution content generation tailored to the user's intent. &nbsp;</li>
<li>Proprietary BigP Backend and Cloud Orchestration serves as the orchestration layer for model training, inference pipelines and content delivery. Integrated with a globally distributed cloud framework, it scales elastically to meet creative surges whether from new user spikes or major feature rollouts.</li>
</ul>

SYTA

Siyata's Merger Partner Core Gaming Sees AI Comic App Users Surge 13x in Japan and South Korea

JP Morgan analyst Daniel Politzer initiates coverage on Ryman Hospitality Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) with a Overweight rating and announces Price Target of $117.

JP Morgan Initiates Coverage On Ryman Hospitality Props with Overweight Rating, Announces Price Target of $117

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Saturday announced detailed results from the ACHIEVE-1 Phase 3 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">diet and exercise alone</a>.
The company released its topline data <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential" rel="noreferrer noopener">from the trial in April</a>.
At 40 weeks, all three doses (3 mg, 12 mg, 36 mg) of orforglipron achieved the primary endpoint of superior A1C reduction.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/46003836/eli-lillys-1-3-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst</a>
In addition, the 12 mg and 36 mg doses showed clinically meaningful and statistically significant reductions in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46041936/lillys-oral-glp-1-orforglipron-showed-compelling-efficacy-and-a-safety-profile-consistent-with-inj" rel="noreferrer noopener">body weight vs. placebo</a>.
In the study, orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks, lowering A1C by 1.3% to 1.6% from a baseline of 8.0% for the efficacy estimand.
In key secondary endpoints, up to 76.2% of participants taking orforglipron achieved the ADA treatment target A1C of &lt;7%, 66.0% achieved an A1C of ≤6.5%, and 25.8% achieved &lt;5.7%, defined as a normal A1C value.
Improvements in A1C were observed as early as four weeks and were accompanied by similar reductions in fasting serum glucose.
In another key secondary endpoint, participants taking the highest dose of orforglipron lost an average of 16.0 lbs (7.9%). 
While participants in ACHIEVE-1 did not appear to reach a weight plateau, longer-duration trials, such as the ATTAIN trials, will provide a comprehensive evaluation of the safety and efficacy of orforglipron for obesity.
While the tolerability profile was in line with the incretin class, William Blair highlights that at the highest dose, nausea, vomiting, and constipation did not appear to subside over time, in contrast with its peptide GLP-1 receptor agonist counterparts.
&#8220;We are less bullish about the prospects of orforglipron in this setting for two reasons: early plateauing and persistent side effects,&#8221; said analyst Andy Hsieh.
<h2 class="wp-block-heading">Once-Weekly Insulin Efsitora</h2>
In addition to the orforglipron data, Eli Lilly also shared promising results for its investigational once-weekly insulin, efsitora.
On Sunday, Eli Lilly announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin <a href="https://www.benzinga.com/pressreleases/25/06/n46043947/lillys-once-weekly-insulin-efsitora-alfa-demonstrated-a1c-reduction-and-a-safety-profile-consisten" target="_blank" rel="noreferrer noopener">and mealtime insulin, respectively</a>.
Eli Lilly released topline results from the QWINT-1 and QWINT-3 trials <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40731728/eli-lillys-once-weekly-insulin-shows-non-inferior-blood-sugar-reduction-vs-frequently-used-daily-" rel="noreferrer noopener">in September 2024</a>.
In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin.
In QWINT-1, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52 for the efficacy estimand.
In the trial, efsitora was titrated to four fixed doses at four-week intervals, as needed for blood glucose control.
In QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec at week 26 for the efficacy estimand. In QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine.
Lilly plans to submit&nbsp;efsitora for adults with type 2 diabetes to global regulatory agencies by the end of this year.
In QWINT-1, efsitora resulted in approximately 40% fewer hypoglycemic events compared to insulin glargine, with estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure of 0.50 with efsitora vs. 0.88 with insulin glargine at 52 weeks. In QWINT-3, these rates were 0.84 with efsitora vs. 0.74 with insulin degludec at 78 weeks.
In QWINT-4, estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure were 6.6 with&nbsp;efsitora vs. 5.9 with insulin glargine at 26 weeks.
Across the three trials, efsitora demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for type 2 diabetes.
Price Action: LLY stock is trading lower by 0.19% to $761.25 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/46036868/obesity-drugs-help-with-weight-loss-but-are-adding-fat-elsewhere" target="_blank" rel="noreferrer noopener">Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere</a></li>
</ul>
Image via Shutterstock

Biotech

Large Cap

Health Care

Eli Lilly's Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns

Guardforce AI Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFAI#NASDAQ">GFAI</a>) on Monday <a target="_blank" href="https://www.benzinga.com/topic/ai" rel="noreferrer noopener">announced that its</a> subsidiary, Guardforce Cash Solutions Security (Thailand) Company Limited (GFCS), has won a three-year renewal with Government Savings Bank (GSB).
GSB one of Thailand&#8217;s state-owned banks adn the renewal deal is effective from June 1, 2025, through May 31, 2028.
This fourth consecutive renewal represents a decade-long partnership between the company and GSB.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/12/42314074/exclusive-guardforce-ai-taps-librum-technologies-to-boost-ai-agent-capabilities" rel="noreferrer noopener">Guardforce AI Taps Librum Technologies To Boost AI Agent Capabilities</a>
Under the renewed agreement, GFCS will continue to provide secure and efficient cash-in-transit and maintenance services for GSB&#8217;s ATM network across Thailand&#8217;s upcountry regions, which covers most of the company&#8217;s ATM services currently handled.
With this renewal, Guardforce AI will secure stable and predictable revenue streams over the next three years, providing the company with a solid financial foundation to invest in innovation and expand its AI-driven solutions, the company said.
In January, GFCS <a target="_blank" href="https://www.benzinga.com/news/25/01/43262471/exclusive-guardforce-ai-expands-partnership-with-government-savings-bank-in-thailand" rel="noreferrer noopener">renewed key contracts</a> with its long-time customer GSB in Thailand. Under two three-year multi-million-dollar contracts, GFCS continued to deliver cash center operations and secure logistics services for coins.
Price Action: GFAI stock closed lower by 3.33% at $1.16 Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/46040754/amazons-powerful-aws-custom-chip-to-get-an-upgrade-why-is-it-important" target="_blank" rel="noreferrer noopener">Amazon&#8217;s Powerful AWS Custom Chip To Get An Upgrade &#8211; Why Is It Important?</a></li>
</ul>
Photo via Company

Market-Moving Exclusives

Exclusives

GFAI

GFAIW

EXCLUSIVE: Guardforce AI Renews 3-Year Deal With Thailand's Government Savings Bank

EXCLUSIVE: Guardforce AI Tells Benzinga 'Ensuring Stable Revenue Streams to Drive Future AI Innovations'

Press Releases

Fitell Corporation Announces $10.0 Million Registered Direct Offering

Fitell Corporation Announces Updated Registered Direct Offering for up to $10.0 Million

Fitell Corporation Announces Closing of Registered Direct Offering for up to $10.0 Million

Fitell Corporation Announces that it will hold its Extraordinary General Meeting of Shareholders on Apri 9, 2025

Fitell Corporation Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement

FTEL

BARK

Big 5 Sporting Goods Corporation - Common Stock

Big 5 Sporting Goods

Barnes & Noble Education, Inc Common Stock

Barnes & Noble Education

Boqii Holding Limited American Depositary Shares (each representing one hundred fifty (150) Class A Ordinary Shares)

Comments

Fitell

Fitell (FTEL) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO